Suppr超能文献

一种在肝细胞癌中上调的新型预后生物标志物SPC24。

A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.

作者信息

Zhu Pengpeng, Jin Junfei, Liao Yan, Li Jun, Yu Xue-Zhong, Liao Weijia, He Songqing

机构信息

Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Guilin Medical University, Guilin, Guangxi, People's Republic of China.

出版信息

Oncotarget. 2015 Dec 1;6(38):41383-97. doi: 10.18632/oncotarget.5510.

Abstract

SPC24 is an important component of the nuclear division cycle 80 (Ndc80) kinetochore complex, which plays an essential role in the coupling of kinetochore to spindle microtubules (MTs) and the accurate segregation of chromosomes during mitosis. However, the functional role of SPC24 in hepatocellular carcinoma (HCC) remains unknown. Here, we detected the expression of SPC24 in HCC and analyzed its association with clinicopathologic features and prognosis of HCC patients. The expression of SPC24 mRNA was investigated in 212 cases of paired HCC and adjacent liver tissues by quantitative real-time PCR (qRT-PCR) and in the tissues of 20 HCC patients by semi-quantitative RT-PCR. Additionally, the expression of SPC24 protein was detected in 69 cases of HCC by immunohistochemistry (IHC) or in 2 cases of HCC tissues by Western-blotting. Furthermore, small interfering RNA (siRNA)-mediated silencing of SPC24 was employed in SMMC7721 and HepG2 human HCC cells to investigate cell proliferation, invasion and apoptosis. Survival curves were plotted using the Kaplan-Meier method, and differences in survival probability were obtained using the log-rank test. Independent predictors associated with disease-free survival (DFS) and overall survival (OS) were analyzed using the Cox proportional-hazards regression model. In this study, we showed that SPC24 was noticeably increased in HCC tissues compared to normal adjacent noncancerous tissues, at both mRNA and protein levels. High expression of SPC24 was significantly correlated with alpha-fetoprotein (AFP) (p = 0.044), median size (p = 0.030), tumor number (p = 0.019), and Barcelona-Clinic Liver Cancer (BCLC) stage (p = 0.015). Kaplan-Meier analysis showed that the DFS and OS of high SPC24 expression group was significantly shorter than that of low SPC24 expression group (p < 0.001; p = 0.001; respectively). The prognostic impact of SPC24 was further confirmed by stratified survival analysis. Importantly, multivariate analysis identified SPC24 upregualtion (p = 0.001), PVTT (p = 0.007), size of tumor > 5 cm (p < 0.001) as independent risk factors of DFS after resection, and SPC24 upregualtion (p < 0.001), PVTT (p = 0.029), size of tumor > 5 cm (p = 0.002), recurrence (p < 0.001) as independent prognostic factors for the OS of HCC patients. Additionally, siRNA-mediated silencing of SPC24 dramatically suppressed cell growth, adhesion, invasion and increased apoptosis in HCC cells. In conclusion, these results showed for the first time that SPC24 expression was significantly up-regulated in HCC, which may act as a novel prognostic biomarker for patients suffering from this deadly disease. Additionally, silence of SPC24 inhibiting HCC cell growth indicated that SPC24 may be a promising molecular target for HCC therapy.

摘要

SPC24是核分裂周期80(Ndc80)动粒复合体的重要组成部分,在动粒与纺锤体微管(MTs)的耦合以及有丝分裂期间染色体的精确分离中起着至关重要的作用。然而,SPC24在肝细胞癌(HCC)中的功能作用仍不清楚。在此,我们检测了SPC24在HCC中的表达,并分析了其与HCC患者临床病理特征及预后的关系。通过定量实时PCR(qRT-PCR)检测了212例配对的HCC及癌旁肝组织中SPC24 mRNA的表达,并通过半定量RT-PCR检测了20例HCC患者组织中的表达。此外,通过免疫组织化学(IHC)检测了69例HCC组织中SPC24蛋白的表达,或通过蛋白质印迹法检测了2例HCC组织中的表达。此外,在SMMC7721和HepG2人HCC细胞中采用小干扰RNA(siRNA)介导沉默SPC24,以研究细胞增殖、侵袭和凋亡。使用Kaplan-Meier方法绘制生存曲线,并使用对数秩检验获得生存概率的差异。使用Cox比例风险回归模型分析与无病生存期(DFS)和总生存期(OS)相关的独立预测因素。在本研究中,我们表明与相邻正常非癌组织相比,HCC组织中SPC24在mRNA和蛋白质水平上均显著增加。SPC24的高表达与甲胎蛋白(AFP)(p = 0.044)、中位大小(p = 0.030)、肿瘤数量(p = 0.019)和巴塞罗那临床肝癌(BCLC)分期(p = 0.015)显著相关。Kaplan-Meier分析表明SPC24高表达组的DFS和OS显著短于SPC24低表达组(分别为p < 0.001;p = 0.001)。分层生存分析进一步证实了SPC24的预后影响。重要的是,多变量分析确定SPC24上调(p = 0.001)、门静脉癌栓(PVTT)(p = 0.007)、肿瘤大小>5 cm(p < 0.001)为切除术后DFS的独立危险因素,SPC24上调(p < 0.001)、PVTT(p = 0.029)、肿瘤大小>5 cm(p = 0.002)、复发(p < 0.001)为HCC患者OS的独立预后因素。此外,siRNA介导沉默SPC24显著抑制了HCC细胞的生长、黏附、侵袭并增加了细胞凋亡。总之,这些结果首次表明SPC24表达在HCC中显著上调,这可能作为这种致命疾病患者的一种新型预后生物标志物。此外,沉默SPC24抑制HCC细胞生长表明SPC24可能是HCC治疗的一个有前景的分子靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/820b/4747413/f46a0ec0393d/oncotarget-06-41383-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验